Abstract
Lung parenchyma involvement in recurrent respiratory papillomatosis (RRP) is rare, can be severe, and has variable outcomes. Although several reports have described the effects of different drugs (interferon alpha, indol-3-carbinol, cidofovir, etc.), there is no standard treatment for lung involvement in respiratory papillomatosis. We discuss herein the controversial effectiveness of cidofovir in light of a new observation of respiratory papillomatosis involving lung parenchyma. The reported case is one of rare pulmonary involvement in RRP and shows the effectiveness of intravenous cidofovir alone on symptoms, high-resolution computed tomography abnormalities, and pulmonary function tests. Aggravation after stopping cidofovir may also be interpreted as an indirect argument for the effectiveness of cidofovir in this case.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
